Sudeep Pharma (SUDEEPPHRM) Share Price Fall Streak: second straight session of decline
- September 10, 2026
- Posted by: Kunal Singla
- Category: News
Sudeep Pharma Share Price Fall Streak is lower for the second straight session, with the stock trading at Rs 1,046.50 as of 09 October 2026 at 9:53:20 AM IST. The move leaves the stock down 5.88% for the day and 10.31% across the full streak from Rs 1,166.85. According to Univest data, the price pattern is confirmed, but no company-specific catalyst is established.
For readers following Sudeep Pharma Share Price Fall Streak, the key point is not just the one-day decline but the sequence of consecutive lower sessions. The company’s market capitalisation stands at Rs 13,179.41 Cr, which places the move in the context of a Mid Cap healthcare stock that is still valued as a premium business. In this kind of run, the cumulative change matters more than the single-session move because it shows how quickly the stock has moved away from the starting point of the streak.
Sudeep Pharma (SUDEEPPHRM) Share Price Fall Streak: Consecutive Decline Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,046.5 |
| Previous Close | Rs 1,111.9 |
| Today's Move | -Rs 65.40 (-5.88%) |
| Open | Rs 1,113.7 |
| High | Rs 1,118.9 |
| Low | Rs 1,045 |
| Market Capitalisation | Rs 13,179.41 crore |
Sudeep Pharma Share Price Fall Streak is trading below the previous close of Rs 1,111.90, after opening at Rs 1,113.70 and touching an intraday high of Rs 1,118.90 before moving to a low of Rs 1,045.00. The latest traded price of Rs 1,046.50 places the stock near the lower end of the day’s range, which is important in a sequence like Sudeep Pharma Share Price Fall Streak because the second straight session has now taken price well below the streak start level.
The stock is down Rs 65.40 or 5.88% from the previous close, and the two-session move has reduced the share price by 10.31% from Rs 1,166.85. Market capitalisation remains Rs 13,179.41 Cr, so Sudeep Pharma Share Price Fall Streak is still a Mid Cap name even after the decline. That combination of a sharp percentage move and a large absolute market value is what keeps Sudeep Pharma Share Price Fall Streak on the radar for readers tracking Sudeep Pharma Share Price Today. The next lens is valuation and what the fundamentals say after the price adjustment.
What the Consecutive Declines Show
Sudeep Pharma Share Price Fall Streak now reflects a two-session pattern rather than an isolated move. The streak start price of Rs 1,166.85, the current price of Rs 1,046.50 and the cumulative fall of 10.31% together show that the stock has already moved materially in a short span. For a reader, that matters because Sudeep Pharma Share Price Fall Streak is no longer about one intraday swing; it is about consecutive lower sessions compounding the effect.
The latest trade also matters because it sits very close to the intraday low, not near the day high. That is a factual sign of where Sudeep Pharma Share Price Fall Streak stands within the current range. As of 09 October 2026 at 9:53:20 AM IST, the pattern is clear on price alone, while the reason for the continuation is not established in the verified data. That leads directly into the fundamental analysis of Sudeep Pharma Share Price Fall Streak.
Sudeep Pharma (SUDEEPPHRM) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 13,179.41 crore |
| P/E Ratio | 68.76x |
| P/B Ratio | 13.59x |
| ROE | 25.37% |
| ROCE | 28.5% |
| EPS | Rs 16.17 |
| Book Value Per Share | Rs 81.8 |
| Dividend Yield | 0.13% |
Sudeep Pharma (SUDEEPPHRM) fundamental metrics show P/E 68.76x, P/B 13.59x, ROE 25.37%, ROCE 28.5%. Taken on their own, these numbers offer context rather than a trading signal.
Sudeep Pharma has a market capitalisation of Rs 13,179.41 crore and falls in the Mid Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 68.76x, P/B at 13.59x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 25.37% and ROCE of 28.5%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 16.17, book value per share of Rs 81.8, dividend yield of 0.13%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 31.28x, median ROE of 11.61%, median ROCE of 13.46%. They set out the fundamental picture and are not a rating on the stock.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 68.76x |
| Benchmark Median P/E | 31.28x |
| Benchmark Average P/E | 47.09x |
| Benchmark P/E Range | 3.56x to 678.22x |
| Company P/B Ratio | 13.59x |
| Benchmark Median P/B | 2.85x |
| Benchmark Average P/B | 4.25x |
| Company ROE | 25.37% |
| Benchmark Median ROE | 11.61% |
| Benchmark Average ROE | 10.59% |
| Company ROCE | 28.5% |
| Benchmark Median ROCE | 13.46% |
| Benchmark Average ROCE | 13.36% |
| Company Market Capitalisation | Rs 13,179.41 crore |
| Benchmark Median Market Cap | Rs 821.44 crore |
| Benchmark Average Market Cap | Rs 14,054.13 crore |
Sudeep Pharma (SUDEEPPHRM) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.
Sudeep Pharma (SUDEEPPHRM) has a P/E ratio of 68.76x, which is above the benchmark median of 31.28x, a difference of +119.82%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Sudeep Pharma (SUDEEPPHRM) has a ROE of 25.37%, which is above the benchmark median of 11.61%, a difference of +118.52%. Sudeep Pharma (SUDEEPPHRM) has a ROCE of 28.5%, which is above the benchmark median of 13.46%, a difference of +111.74%.
Track stocks among today's decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,27,861.41 | 34.76 | 4.86 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,54,318.9 | 85.21 | 14.11 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,79,153.26 | 81.53 | 19.81 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,15,111.94 | 24.65 | 4.13 | 19.69 | 21.39 |
| Laurus Labs | LAURUSLABS | 1,11,034.16 | 98.83 | 19.16 | 18.31 | 18.2 |
Sudeep Pharma (SUDEEPPHRM) has a P/E ratio of 68.76x compared with the displayed peer median of 81.53x. The comparison is relative and should not be read as a recommendation. Its ROE of 25.37% compares with a peer median of 18.31% across the companies shown in the table. ROCE stood at 28.5% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Sudeep Pharma (SUDEEPPHRM) has a market capitalisation of Rs 13,179.41 crore. All 5 peers shown have a larger market capitalisation.
Why Investors Are Watching Sudeep Pharma
- Sudeep Pharma Share Price Fall Streak has extended to a second straight session, so the move is about a pattern rather than a one-off fall.
- The stock is trading at Rs 1,046.50, which is below the previous close and below the streak start price of Rs 1,166.85.
- Market capitalisation of Rs 13,179.41 Cr keeps Sudeep Pharma Share Price Fall Streak in the Mid Cap bracket.
- P/E of 68.76 and P/B of 13.59 still point to a premium valuation even after the decline.
- ROE of 25.37% and ROCE of 28.5% remain strong against the healthcare benchmark, which helps frame the stock’s stock analysis.
About Sudeep Pharma
Sudeep Pharma operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. For readers tracking Sudeep Pharma Share Price Fall Streak, the relevant business context is that the company is part of a sector where valuation, earnings quality and return ratios often matter as much as daily price moves. The company’s current market capitalisation and profitability ratios show that it is a meaningful listed name in its space.
In this streak lens, the important point is simple: Sudeep Pharma Share Price Fall Streak is moving lower, but the business still sits within a premium-quality industry backdrop based on the numbers shown. That is the context investors usually need before reading the next price update, financial results or company news.
Track Sudeep Pharma Share Price on Univest
Use Sudeep Pharma (SUDEEPPHRM) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners and related market analysis.
You can track Sudeep Pharma Share Price on Univest for live share price updates, fundamental ratios, 52-week levels and market insights. For Sudeep Pharma Share Price Fall Streak, that helps keep the latest price action, valuation and sector comparison in one place without breaking the flow of Sudeep Pharma stock analysis. Univest also makes it easier to follow the company’s share price fall and share price update context as the market moves.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).
Frequently Asked Questions
Why is Sudeep Pharma Share Price Fall Streak in focus today?
Ans. Sudeep Pharma Share Price Fall Streak is in focus because the stock is lower for a second straight session. It is trading at Rs 1,046.50, down 5.88% from the previous close, with the streak now showing a 10.31% cumulative.
What is the current price in Sudeep Pharma Share Price Fall Streak?
Ans. The latest traded price is Rs 1,046.50 as of 09 October 2026 at 9:53:20 AM IST. In Sudeep Pharma Share Price Fall Streak, that price is also below the session open and close reference.
How much has Sudeep Pharma fallen in this streak?
Ans. Sudeep Pharma Share Price Fall Streak has fallen 10.31% across the full two-session run from the streak start price of Rs 1,166.85. The latest session alone is down 5.88%, showing that the decline has extended rather than paused.
What is the market capitalisation of Sudeep Pharma ?
Ans. Sudeep Pharma has a market capitalisation of Rs 13,179.41 Cr. In the context of Sudeep Pharma Share Price Fall Streak, that keeps the company in the Mid Cap category while it remains a meaningful healthcare stock.
What do the valuation ratios say about Sudeep Pharma Share Price Fall Streak?
Ans. Sudeep Pharma Share Price Fall Streak is trading at a P/E of 68.76 and a P/B of 13.59. Those ratios remain above the healthcare benchmark median, so the stock still looks premium relative to the industry screen.
How do ROE and ROCE look for Sudeep Pharma ?
Ans. ROE stands at 25.37% and ROCE at 28.5%. For Sudeep Pharma Share Price Fall Streak, those return ratios are stronger than the industry medians in the Pharmaceuticals & Drugs set and give useful fundamental context.
How does Sudeep Pharma compare with healthcare peers?
Ans. Sudeep Pharma Share Price Fall Streak has a smaller market capitalisation than Sun Pharmaceutical Industries, Divi’s Laboratories, Torrent Pharmaceuticals and Zydus Lifesciences Its P/E is also above several peers but below some higher-valued names.
What is the EPS and book value for Sudeep Pharma ?
Ans. EPS is Rs 16.17 and book value is Rs 81.8. In Sudeep Pharma Share Price Fall Streak, these figures matter because the fall changes the trading multiple, while the earnings and book-value base itself stays the same.
Where can I track Sudeep Pharma Share Price on Univest?
Ans. You can track Sudeep Pharma Share Price on Univest for live share price, fundamental ratios, 52-week levels and market insights. That makes it easier to follow Sudeep Pharma Share Price Fall Streak alongside valuation and sector context.